Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in Chronic Spontaneous Urticaria
NCT06228560Phase 2Completed
- Sponsor
- LongBio Pharma
- Start
- Jan 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in chronic spontaneous urticaria (CSU), sponsored by LongBio Pharma. Started Jan 2024; status: completed.
02
Drugs
LP-003
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06228560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228560.